Obesity-Related Hypertension

1. Organization WH. Obesity and overweight. 2018. Search in Google Scholar

2. Fox A, Feng W, Asal V. What is driving global obesity trends? Globalization or “modernization”? Global Health 2019;15:32. Search in Google Scholar

3. NCD Risk Factor Collaboration (NCD-RisC) Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19.2 million participants. Lancet 2016;387:1377-96.10.1016/S0140-6736(16)30054-X Search in Google Scholar

4. Narkiewicz K. Obesity and hypertension–the issue is more complex than we thought. Nephrol Dial Transplant. 2006; 21:264–267.10.1093/ndt/gfi290 Search in Google Scholar

5. Crump C, Sundquist J, Winkleby MA, Sundquist K. Interactive effects of physical fitness and body mass index on the risk of hypertension. JAMA Intern Med. 2016; 176:210–216.10.1001/jamainternmed.2015.7444 Search in Google Scholar

6. Juonala M, Magnussen CG, Berenson GS, Venn A, Burns TL, Sabin MA, Srinivasan SR, Daniels SR, Davis PH, Chen W, et al. Childhood adiposity, adult adiposity, and cardiovascular risk factors. N Engl J Med. 2011; 365:1876–1885.10.1056/NEJMoa1010112 Search in Google Scholar

7. World Health Organization. Waist circumference and waist-hip ratio: report of a WHO expert consultation, Geneva, 8-11 December 2011. Search in Google Scholar

8. Wofford MR, Anderson DC, Jr, Brown CA, et al. Antihypertensive effect of alpha- and beta-adrenergic blockade in obese and lean hypertensive subjects. Am J Hypertens 2001;14:694-8.10.1016/S0895-7061(01)01293-6 Search in Google Scholar

9. Lambert EA, Esler MD, Schlaich MP, et al. Obesity-Associated Organ Damage and Sympathetic Nervous Activity. Hypertension 2019;73:1150-9.10.1161/HYPERTENSIONAHA.118.1167631067200 Search in Google Scholar

10. Gentile CL, Orr JS, Davy BM, et al. Modest weight gain is associated with sympathetic neural activation in nonobese humans. Am J Physiol Regul Integr Comp Physiol 2007;292:R1834-8.10.1152/ajpregu.00876.200617218435 Search in Google Scholar

11. Vaz M, Jennings G, Turner A, et al. Regional sympathetic nervous activity and oxygen consumption in obese normotensive human subjects. Circulation 1997;96:3423-9.10.1161/01.CIR.96.10.3423 Search in Google Scholar

12. Dewan NA, Nieto FJ, Somers VK. Intermittent hypoxemia and OSA: implications for comorbidities. Chest 2015;147:266-74.10.1378/chest.14-0500428508025560865 Search in Google Scholar

13. Cabandugama PK, Gardner MJ, Sowers JR. The Renin Angiotensin Aldosterone System in Obesity and Hypertension: Roles in the Cardiorenal Metabolic Syndrome. Med Clin North Am 2017;101:129-37.10.1016/j.mcna.2016.08.009512554227884224 Search in Google Scholar

14. Schütten MT, Houben AJ, de Leeuw PW, et al. The Link Between Adipose Tissue Renin-Angiotensin-Aldosterone System Signaling and Obesity-Associated Hypertension. Physiology (Bethesda) 2017;32:197-209.10.1152/physiol.00037.2016 Search in Google Scholar

15. Yiannikouris F, Karounos M, Charnigo R, et al. Adipocyte-specific deficiency of angiotensinogen decreases plasma angiotensinogen concentration and systolic blood pressure in mice. Am J Physiol Regul Integr Comp Physiol 2012;302:R244-51.10.1152/ajpregu.00323.2011 Search in Google Scholar

16. Jeon JH, Kim KY, Kim JH, et al. A novel adipokine CTRP1 stimulates aldosterone production. FASEB J 2008;22:1502-11.10.1096/fj.07-9412com Search in Google Scholar

17. Ehrhart-Bornstein M, Lamounier-Zepter V, Schraven A, et al. Human adipocytes secrete mineralocorticoid-releasing factors. Proc Natl Acad Sci U S A 2003;100: 14211-6.10.1073/pnas.2336140100 Search in Google Scholar

18. Grassi G, Seravalle G, Dell’Oro R, et al. Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: results of the CROSS study. J Hypertens 2003;21:1761-9.10.1097/00004872-200309000-00027 Search in Google Scholar

19. Dorresteijn JA, Schrover IM, Visseren FL, et al. Differential effects of renin-angiotensin-aldosterone system inhibition, sympathoinhibition and diuretic therapy on endothelial function and blood pressure in obesity-related hypertension: a double-blind, placebo-controlled cross-over trial. J Hypertens 2013;31:393-403.10.1097/HJH.0b013e32835b6c02 Search in Google Scholar

20. Williams B, MacDonald TM, Morant S, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet 2015;386:2059-68.10.1016/S0140-6736(15)00257-3 Search in Google Scholar

21. Dwyer TM, Banks SA, Alonso-Galicia M, et al. Distribution of renal medullary hyaluronan in lean and obese rabbits. Kidney Int 2000;58:721-9.10.1046/j.1523-1755.2000.00218.x10916095 Search in Google Scholar

22. Kambham N, Markowitz GS, Valeri AM, et al. Obesity-related glomerulopathy: an emerging epidemic. Kidney Int 2001;59:1498-509.10.1046/j.1523-1755.2001.0590041498.x11260414 Search in Google Scholar

23. Kotsis V, Stabouli S, Papakatsika S, et al. Mechanisms of obesity-induced hypertension. Hypertens Res 2010;33:386-93.10.1038/hr.2010.920442753 Search in Google Scholar

24. Hall ME, do Carmo JM, da Silva AA, et al. Obesity, hypertension, and chronic kidney disease. Int J Nephrol Renovasc Dis 2014;7:75-88.10.2147/IJNRD.S39739393370824600241 Search in Google Scholar

25. Savoia C, Volpe M, Alonzo A, Rossi C, Rubattu S. Natriuretic peptides and cardiovascular damage in the metabolic syndrome: molecular mechanisms and clinical implications. Clin Sci (Lond) 2010;118:231–240.10.1042/CS2009020419886866 Search in Google Scholar

26. Bordicchia M, Liu D, Amri EZ, Ailhaud G, Dessi-Fulgheri P, Zhang C, Takahashi N, Sarzani R, Collins S. Cardiac natriuretic peptides act via p38 MAPK to induce the brown fat thermogenic program in mouse and human adipocytes. J Clin Invest. 2012;122:1022–1036.10.1172/JCI59701328722422307324 Search in Google Scholar

27. Zois NE, Bartels ED, Hunter I, Kousholt BS, Olsen LH, Goetze JP. Natriuretic peptides in cardiometabolic regulation and disease. Nat Rev Cardiol. 2014;11: 403–412.10.1038/nrcardio.2014.6424820868 Search in Google Scholar

28. Hall JE, Brands MW, Dixon WN, Smith MJ., Jr Obesity-induced hypertension. Renal function and systemic hemodynamics. Hypertension. 1993;22:292–299.10.1161/01.HYP.22.3.292 Search in Google Scholar

29. Wildman RP, Mackey RH, Bostom A, Thompson T, Sutton-Tyrrell K. Measures of obesity are associated with vascular stiffness in young and older adults. Hypertension. 2003;42:468–473.10.1161/01.HYP.0000090360.78539.CD12953016 Search in Google Scholar

30. Lyon CJ, Law RE, Hsueh WA. Minireview: adiposity, inflammation, and atherogenesis. Endocrinology. 2003;144:2195-2200.10.1210/en.2003-028512746274 Search in Google Scholar

31. Grassi G, Seravalle G, Cattaneo BM, Bolla G, Lafranchi A, Colombo M, Giannattasio C, Brunani A, Cavagnini F, Mancia G. Sympathetic activation in obese normotensive subjects. Hypertension 1995; 25: 560-563.10.1161/01.HYP.25.4.560 Search in Google Scholar

32. Hall JE, Crook ED, Jones DW, Wolford MR, Dubbert PM. Mechanisms of obesity-associated cardiovascular and renal disease. Am J Med Sci 2002; 324: 127-137.10.1097/00000441-200209000-0000312240710 Search in Google Scholar

33. Kambham N, Markowitz GS, Valeri AM, D’Agati VD. Obesity-related glomerulopathy: an emerging epidemic. Kidney Int 2001; 59: 1498-1509.10.1046/j.1523-1755.2001.0590041498.x11260414 Search in Google Scholar

34. Deji N, Kume S, Araki S, Soumura M, Sugimoto T, Isshiki K, Chin-Kanasaki M, Chin-Kanasaki M, Sakaguchi M, Koya D, Haneda M, Kashiwagi A, Uzu T. Structural and functional changes in the kidneys of high-fat diet-induced obese mice. Am J Physiol Renal Physiol 2009; 296: F118–F126.10.1152/ajprenal.00110.200818971213 Search in Google Scholar

35. Després JP. Body fat distribution and risk of cardiovascular disease: an update. Circulation 2012;126:1301-13.10.1161/CIRCULATIONAHA.111.06726422949540 Search in Google Scholar

36. Hall ME, do Carmo JM, da Silva AA, et al. Obesity, hypertension, and chronic kidney disease. Int J Nephrol Renovasc Dis 2014;7:75-88.10.2147/IJNRD.S39739393370824600241 Search in Google Scholar

37. DeFronzo RA, Cooke CR, Andres R, et al. The effect of insulin on renal handling of sodium, potassium, calcium, and phosphate in man. J Clin Invest 1975;55:845-55.10.1172/JCI1079963018221120786 Search in Google Scholar

38. Muniyappa R, Sowers JR. Role of insulin resistance in endothelial dysfunction. Rev Endocr Metab Disord 2013;14:5-12.10.1007/s11154-012-9229-1359411523306778 Search in Google Scholar

39. Hall JE. Hyperinsulinemia: a link between obesity and hypertension? Kidney Int 1993; 43: 1402–1417. Search in Google Scholar

40. Creager MA, Liang CS, Coffman JD. Beta adrenergic-mediated vasodilator response to insulin in the human forearm. Am Soc Pharm Exper Ther 1985; 235: 709-714. Search in Google Scholar

41. Kuo JJ, Jones OB, Hall JE. Inhibition of NO synthesis enhances chronic cardiovascular and renal actions of leptin. Hypertension 2001; 37: 670-676.10.1161/01.HYP.37.2.670 Search in Google Scholar

42. Knudson JD, Payne GA, Borbouse L, Tune JD. Leptin and mechanisms of endothelial dysfunction and cardiovascular disease. Curr Hypertens Rep 2008; 10: 434-439.10.1007/s11906-008-0082-218959828 Search in Google Scholar

43. Korda M, Kubant R, Patton S, Malinski T. Leptin-induced endothelial dysfunction in obesity. Am J Physiol Heart Circ Physiol 2008; 295: H1514-H1521.10.1152/ajpheart.00479.2008259350718689498 Search in Google Scholar

44. Lundberg JM, Pernow J, Franco-Cereceda A, Rudehill A. Effects of antihypertensive drugs on sympathetic vascular control in relation to NPY. J Cardiovasc Pharmacol 1987; 10 (Suppl 12): S51-S68.10.1097/00005344-198710012-00008 Search in Google Scholar

45. Guillod-Maximin E, Roy AF, Vacher CM, Aubourg A, Bailleux V, Lossignol A, Penicaud L, Parquet M, Taonis M. Adiponectin receptors are expressed in hypothalamus and colocalized with POMC and NPY in rodent arcuate neurons. J Endocrinol 2009; 200: 93-105.10.1677/JOE-08-034818971219 Search in Google Scholar

46. Saruta T. Mechanism of glucocorticoid-induced hypertension. Hypertens Res 1996; 19: 1–8.10.1291/hypres.19.18829818 Search in Google Scholar

47. Whitworth JA, Schyvens CG, Zhang Y, Mangos GJ, Kelly JJ. Glucocorticoid-induced hypertension: from mouse to man. Clin Exp Pharmacol Physiol 2001; 28: 993-996.10.1046/j.1440-1681.2001.03584.x11903301 Search in Google Scholar

48. Bentley-Lewis R, Adler GK, Perlstein T, Seely EW, Hopkins PN, Williams GH, Garg R. Body mass index predicts aldosterone production in normotensive adults on a high-salt diet. J Clin Endocrinol Metab 2007; 92:4472-4475.10.1210/jc.2007-1088442858417726083 Search in Google Scholar

49. Goodfriend TL, Kelley DE, Goodpaster BH, Winters SJ. Visceral obesity and insulin resistance are associated with plasma aldosterone levels in women. Obes Res 1999; 7:355-362.10.1002/j.1550-8528.1999.tb00418.x10440591 Search in Google Scholar

50. Williams JS, Williams GH. 50 anniversary of aldosterone. J Clin Endocrinol Metab 2003; 88:2364-2372.10.1210/jc.2003-03049012788829 Search in Google Scholar

51. Lai L, Feng X, Liu D, Chen J, Zhang Y, Niu B, Gu Y, Cai H. Dietary salt modulates the sodium chloride cotransporter expression likely through an aldosterone-mediated WNK4-ERK1/2 signaling pathway. Pflugers Arch 2012; 463:477-485.10.1007/s00424-011-1062-y22200850 Search in Google Scholar

52. Chiga M, Rai T, Yang SS, Ohta A, Takizawa T, Sasaki S, Uchida S. Dietary salt regulates the phosphorylation of OSR1/SPAK kinases and the sodium chloride cotransporter through aldosterone. Kidney Int 2008; 74:1403-1409.10.1038/ki.2008.45118800028 Search in Google Scholar

53. Engeli S, Böhnke J, Gorzelniak K, Janke J, Schling P, Bader M, Luft FC, Sharma AM. Weight loss and the reninangiotensin-aldosterone system. Hypertension 2005; 45:356-362.10.1161/01.HYP.0000154361.47683.d315630041 Search in Google Scholar

54. Engeli S, Sharma A. Emerging concepts in the pathophysiology and treatment of obesity-associated hypertension. Curr Opin Cardiol 2002; 17: 355-359.10.1097/00001573-200207000-0000612151869 Search in Google Scholar

55. Angrisani L, Santonicola A, Iovino P, et al. IFSO Worldwide Survey 2016: Primary, Endoluminal, and Revisional Procedures. Obes Surg 2018;28:3783-94.10.1007/s11695-018-3450-230121858 Search in Google Scholar

56. Buchwald H, Oien DM. Metabolic/bariatric surgery worldwide 2011. Obes Surg 2013;23:427-36.10.1007/s11695-012-0864-023338049 Search in Google Scholar

57. English WJ, DeMaria EJ, Brethauer SA, et al. American Society for Metabolic and Bariatric Surgery estimation of metabolic and bariatric procedures performed in the United States in 2016. Surg Obes Relat Dis 2018;14:259-63.10.1016/j.soard.2017.12.01329370995 Search in Google Scholar

58. Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA 2004;292:1724-37.10.1001/jama.292.14.172415479938 Search in Google Scholar

59. Chang SH, Stoll CR, Song J, et al. The effectiveness and risks of bariatric surgery: an updated systematic review and meta-analysis, 2003-2012. JAMA Surg 2014;149:275-87.10.1001/jamasurg.2013.3654396251224352617 Search in Google Scholar

60. Gloy VL, Briel M, Bhatt DL, et al. Bariatric surgery versus non-surgical treatment for obesity: a systematic review and meta-analysis of randomised controlled trials. BMJ 2013;347:f5934.10.1136/bmj.f5934380636424149519 Search in Google Scholar

61. Puzziferri N, Roshek TB, 3rd, Mayo HG, et al. Long-term follow-up after bariatric surgery: a systematic review. JAMA 2014;312:934-42.10.1001/jama.2014.10706440900025182102 Search in Google Scholar

62. Kang JH, Le QA. Effectiveness of bariatric surgical procedures: A systematic review and network meta-analysis of randomized controlled trials. Medicine (Baltimore) 2017; 96:e8632.10.1097/MD.0000000000008632570482929145284 Search in Google Scholar